Compare CBZ & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBZ | ANAB |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 1996 | 2015 |
| Metric | CBZ | ANAB |
|---|---|---|
| Price | $32.94 | $62.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $41.33 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 804.2K | 567.5K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.62 | 91.02 |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $922,003,000.00 | $234,603,000.00 |
| Revenue This Year | $3.92 | N/A |
| Revenue Next Year | $4.12 | $52.14 |
| P/E Ratio | $17.82 | ★ N/A |
| Revenue Growth | 7.79 | ★ 157.01 |
| 52 Week Low | $24.29 | $17.11 |
| 52 Week High | $77.91 | $73.30 |
| Indicator | CBZ | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 67.77 | 51.98 |
| Support Level | $24.87 | $53.46 |
| Resistance Level | $54.79 | $69.56 |
| Average True Range (ATR) | 1.33 | 5.32 |
| MACD | 0.42 | 0.01 |
| Stochastic Oscillator | 85.38 | 64.47 |
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).